EA202191014A1 - Производные 4-пиразин-2-илметил-морфолина и их применение в качестве лекарственного средства - Google Patents

Производные 4-пиразин-2-илметил-морфолина и их применение в качестве лекарственного средства

Info

Publication number
EA202191014A1
EA202191014A1 EA202191014A EA202191014A EA202191014A1 EA 202191014 A1 EA202191014 A1 EA 202191014A1 EA 202191014 A EA202191014 A EA 202191014A EA 202191014 A EA202191014 A EA 202191014A EA 202191014 A1 EA202191014 A1 EA 202191014A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ilmethyl
pyrazine
medicinal product
morpholine derivatives
morpholines
Prior art date
Application number
EA202191014A
Other languages
English (en)
Inventor
Риккардо Джованнини
Анджело Чечи
Корнелия Дорнер-Циоссек
Роланд Пфау
Дитер Виденмайер
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA202191014A1 publication Critical patent/EA202191014A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Настоящее изобретение относится к новым 4-пиразин-2-илметил-морфолинам общей формулы Aспособам их приготовления, фармацевтическим композициям, которые их содержат, и их применению в терапии, в особенности для лечения или предотвращения состояний, имеющих ассоциацию с NR2B отрицательными аллостерическими модулирующими свойствами.
EA202191014A 2018-10-17 2019-10-16 Производные 4-пиразин-2-илметил-морфолина и их применение в качестве лекарственного средства EA202191014A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18200943 2018-10-17
PCT/EP2019/078027 WO2020079039A1 (en) 2018-10-17 2019-10-16 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament

Publications (1)

Publication Number Publication Date
EA202191014A1 true EA202191014A1 (ru) 2021-11-09

Family

ID=63878518

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191014A EA202191014A1 (ru) 2018-10-17 2019-10-16 Производные 4-пиразин-2-илметил-морфолина и их применение в качестве лекарственного средства

Country Status (35)

Country Link
US (2) US11166958B2 (ru)
EP (1) EP3867244B1 (ru)
JP (1) JP7093468B2 (ru)
KR (1) KR20210079325A (ru)
CN (1) CN112888685B (ru)
AR (1) AR116711A1 (ru)
AU (1) AU2019362330B2 (ru)
BR (1) BR112021004993A2 (ru)
CA (1) CA3113308A1 (ru)
CL (1) CL2021000858A1 (ru)
CO (1) CO2021004612A2 (ru)
CR (1) CR20210184A (ru)
DK (1) DK3867244T3 (ru)
DO (1) DOP2021000069A (ru)
EA (1) EA202191014A1 (ru)
EC (1) ECSP21027009A (ru)
ES (1) ES2940184T3 (ru)
FI (1) FI3867244T3 (ru)
HR (1) HRP20230249T1 (ru)
HU (1) HUE061891T2 (ru)
IL (1) IL282142B2 (ru)
JO (1) JOP20210075A1 (ru)
LT (1) LT3867244T (ru)
MA (1) MA53898B1 (ru)
MX (1) MX2021004418A (ru)
PE (1) PE20211278A1 (ru)
PH (1) PH12021550834A1 (ru)
PL (1) PL3867244T3 (ru)
PT (1) PT3867244T (ru)
RS (1) RS63988B1 (ru)
SA (1) SA521421756B1 (ru)
SG (1) SG11202103806VA (ru)
SI (1) SI3867244T1 (ru)
TW (1) TWI828779B (ru)
WO (1) WO2020079039A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3980401A1 (en) * 2019-06-04 2022-04-13 Boehringer Ingelheim International GmbH Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
AU2002338334B8 (en) 2001-04-03 2008-09-18 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists
MXPA04000737A (es) * 2001-07-24 2004-07-08 Richter Gedeon Vegyeszet Derivados de piperidina como antagonistas receptores de nmda.
US7855201B2 (en) * 2005-12-06 2010-12-21 Merck Sharp & Dohme. Corp. Morpholine carboxamide prokineticin receptor antagonists
US20110319416A1 (en) * 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
WO2012128582A2 (en) 2011-03-23 2012-09-27 Hyundai Pharm Co., Ltd. A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
KR101684816B1 (ko) 2012-10-18 2016-12-20 에프. 호프만-라 로슈 아게 mGluR5 수용체 활성의 조절제로서 에틴일 유도체
US9676757B2 (en) 2014-02-27 2017-06-13 Merck Patent Gmbh Heterocyclic compounds as NaV channel inhibitors and uses thereof
WO2016029146A1 (en) 2014-08-22 2016-02-25 University Of Washington Specific inhibitors of methionyl-trna synthetase
WO2017066368A1 (en) * 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Selective nr2b antagonists

Also Published As

Publication number Publication date
AR116711A1 (es) 2021-06-02
TW202031262A (zh) 2020-09-01
CO2021004612A2 (es) 2021-04-30
CN112888685B (zh) 2023-09-22
MA53898A (fr) 2022-01-26
US11166958B2 (en) 2021-11-09
LT3867244T (lt) 2023-03-10
HUE061891T2 (hu) 2023-09-28
IL282142A (en) 2021-05-31
SA521421756B1 (ar) 2023-02-12
US20210393644A1 (en) 2021-12-23
KR20210079325A (ko) 2021-06-29
ECSP21027009A (es) 2021-05-31
AU2019362330A1 (en) 2021-04-08
MX2021004418A (es) 2021-07-06
SG11202103806VA (en) 2021-05-28
PL3867244T3 (pl) 2023-05-22
CN112888685A (zh) 2021-06-01
EP3867244B1 (en) 2023-01-18
IL282142B1 (en) 2023-12-01
WO2020079039A1 (en) 2020-04-23
DK3867244T3 (da) 2023-05-01
SI3867244T1 (sl) 2023-04-28
JOP20210075A1 (ar) 2023-01-30
PE20211278A1 (es) 2021-07-19
JP2022505080A (ja) 2022-01-14
US20200121691A1 (en) 2020-04-23
ES2940184T3 (es) 2023-05-04
BR112021004993A2 (pt) 2021-06-08
CA3113308A1 (en) 2020-04-23
CR20210184A (es) 2021-05-26
PT3867244T (pt) 2023-02-22
CL2021000858A1 (es) 2021-10-01
DOP2021000069A (es) 2021-05-31
HRP20230249T1 (hr) 2023-04-14
FI3867244T3 (fi) 2023-03-20
RS63988B1 (sr) 2023-03-31
JP7093468B2 (ja) 2022-06-29
IL282142B2 (en) 2024-04-01
TWI828779B (zh) 2024-01-11
EP3867244A1 (en) 2021-08-25
PH12021550834A1 (en) 2021-10-04
AU2019362330B2 (en) 2024-03-28
MA53898B1 (fr) 2023-03-31

Similar Documents

Publication Publication Date Title
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
EA201590457A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
PH12016502352A1 (en) Pharmaceutical composition
CY1122689T1 (el) Παραγωγα πυραζολιου χρησιμα ως αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
TW201613578A (en) Pharmaceutical combinations
EP4342473A3 (en) Compounds useful in hiv therapy
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
NZ745185A (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
CY1124744T1 (el) Παραγωγα ιμιδαζοπυριδινης και η χρηση αυτων ως φαρμακο
BR112017027285A2 (pt) ?cocristal, composição farmacêutica e método para o tratamento de uma doença?
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
EA202191014A1 (ru) Производные 4-пиразин-2-илметил-морфолина и их применение в качестве лекарственного средства
PH12018501563A1 (en) Indane derivatives as mglur7 modulators
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
PL431336A1 (pl) Lipopeptydy, kompozycja farmaceutyczna, kompozycja kosmetyczna oraz lipopeptydy do zastosowania jako lek
EA201991746A1 (ru) Производные пиразола в качестве ингибиторов бромодомена
EA201990261A1 (ru) 2,5-двузамещенные 3-метилпиразины и 2,5,6-тризамещенные 3-метилпиразины в качестве аллостерических ингибиторов shp2